Drugs / GEM333
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03516760 | Apr 2018 → Jun 2022 | acute myeloid leukemia | AvenCell Europe GmbH | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEM333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03516760 ↗ |
| Route | Intravenous | “administered intravenously” NCT03516760 ↗ |
| Target | CD33 | “a CD33 targeted bispecific antibody engaging T-cells” NCT03516760 ↗ |